6.03
-0.08(-1.31%)
Currency In USD
| Previous Close | 6.11 |
| Open | 6.15 |
| Day High | 6.28 |
| Day Low | 6.03 |
| 52-Week High | 10.37 |
| 52-Week Low | 2.41 |
| Volume | 856,456 |
| Average Volume | 1.57M |
| Market Cap | 469.55M |
| PE | -2.16 |
| EPS | -2.79 |
| Moving Average 50 Days | 5.61 |
| Moving Average 200 Days | 4.54 |
| Change | -0.08 |
If you invested $1000 in Solid Biosciences Inc. (SLDB) since IPO date, it would be worth $17.77 as of August 18, 2025 at a share price of $6.03. Whereas If you bought $1000 worth of Solid Biosciences Inc. (SLDB) shares 5 years ago, it would be worth $131.8 as of August 18, 2025 at a share price of $6.03.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
GlobeNewswire Inc.
Jul 23, 2025 12:00 PM GMT
- SGT-501 has now received FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations - - Potential first-in-class therapy with FDA IND clearance and Health Canada CTA approval designed to address underlying causes of CPVT, a life-threatenin
Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
GlobeNewswire Inc.
Jul 08, 2025 8:05 PM GMT
- SGT-501 is a novel gene therapy for rare, life-threatening, genetic arrhythmogenic disease with no approved therapies - - SGT-501 has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA - - Solid expects to initiate
Solid Biosciences to Participate at the Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 28, 2025 12:00 PM GMT
CHARLESTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced that Bo Cumbo, P